Teva weighs options for PGT Healthcare
This article was originally published in OTC Bulletin & The Rose Sheet
Teva is reviewing its options for PGT Healthcare, its international OTC joint venture with Procter & Gamble (P&G).
You may also be interested in...
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.
The renamed Expert Panel for Cosmetic Ingredient Safety has its own website now, which includes the conflict of interest statement its members are expected to sign. The panel will meet virtually 8-9 June to consider a raft of ingredient reports in various stages of development at Cosmetic Ingredient Review.
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.